Quarterly report · Q2
8086.TEDINET S100PL3A
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥260.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥494.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥242.1bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥6.4bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥12.9bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥11.6bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥27.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥12.4bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥13.1bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥12.1bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥6.3bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥7.3bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥7.1bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥8.1bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥1.01T | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥930.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥888.3bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥768.6bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥730.5bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥237.2bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥199.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥190.8bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥95.5bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥95.3bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥89.9bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥90.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥75.0bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥85.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥3.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥68.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥25.5bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥41.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥78.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥47.4bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥23.8bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥10.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥7.3bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥38.34 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥5.99 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥82.5 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥44.78 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.54 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥33.97 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥77.42 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥44.65 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 22.0% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.9% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.9% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 54
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥2.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥340m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥168m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥18.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥18.6bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥15.3bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥203.9bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥200.8bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥18.6bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥44.9bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥34.1bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥10.8bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥849m |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥28.0bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥25.0bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3.0bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.1bn |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥276.8bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥260.0bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥16.8bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥21.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥278.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥260.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥18.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥21.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-09-30 | ¥1.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-09-30 | ¥295m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥988m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-09-30 | ¥205m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥17.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥17.6bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥11.7bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥186.8bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥183.4bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥3.3bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥19.6bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥45.2bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥35.0bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥10.2bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥26.5bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥23.4bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥2.1bn |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥258.4bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥241.8bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥16.6bn |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥24.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥259.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥242.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥17.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥24.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 643
| Item | Context | Value | Unit |
|---|---|---|---|
| Profit loss attributable to non controlling interests | CurrentYTDDuration | 798000000 | JPY |
| Profit loss attributable to owners of parent | Prior1YTDDuration | 7303000000 | JPY |
| Profit loss attributable to owners of parent | CurrentYTDDuration | 6252000000 | JPY |
| Profit loss | Prior1YTDDuration | 8079000000 | JPY |
| Profit loss | CurrentYTDDuration | 7051000000 | JPY |
| Valuation difference on available for sale securities net of tax oci | Prior1YTDDuration | 607000000 | JPY |
| Valuation difference on available for sale securities net of tax oci | CurrentYTDDuration | -1662000000 | JPY |
| Deferred gains or losses on hedges net of tax oci | Prior1YTDDuration | 18000000 | JPY |
| Deferred gains or losses on hedges net of tax oci | CurrentYTDDuration | 31000000 | JPY |
| Foreign currency translation adjustment net of tax oci | Prior1YTDDuration | 11777000000 | JPY |
| Foreign currency translation adjustment net of tax oci | CurrentYTDDuration | 31756000000 | JPY |
| Remeasurements of defined benefit plans net of tax oci | Prior1YTDDuration | -54000000 | JPY |
| Remeasurements of defined benefit plans net of tax oci | CurrentYTDDuration | 403000000 | JPY |
| Share of other comprehensive income of associates accounted for using equity method oci | Prior1YTDDuration | 95000000 | JPY |
| Share of other comprehensive income of associates accounted for using equity method oci | CurrentYTDDuration | 1681000000 | JPY |
| Other comprehensive income | Prior1YTDDuration | 12444000000 | JPY |
| Other comprehensive income | CurrentYTDDuration | 32210000000 | JPY |
| Comprehensive income | Prior1YTDDuration | 20524000000 | JPY |
| Comprehensive income | CurrentYTDDuration | 39261000000 | JPY |
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | 19469000000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | 38020000000 | JPY |
| Comprehensive income attributable to non controlling interests | Prior1YTDDuration | 1054000000 | JPY |
| Comprehensive income attributable to non controlling interests | CurrentYTDDuration | 1240000000 | JPY |
| Income before income taxes | Prior1YTDDuration | 12120000000 | JPY |
| Income before income taxes | CurrentYTDDuration | 13145000000 | JPY |
| Depreciation and amortization ope cf | Prior1YTDDuration | 20695000000 | JPY |
| Depreciation and amortization ope cf | CurrentYTDDuration | 21538000000 | JPY |
| Amortization of goodwill ope cf | Prior1YTDDuration | 1543000000 | JPY |
| Amortization of goodwill ope cf | CurrentYTDDuration | 1180000000 | JPY |
| Equity in earnings losses of affiliates ope cf | Prior1YTDDuration | 441000000 | JPY |
| Equity in earnings losses of affiliates ope cf | CurrentYTDDuration | 629000000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | Prior1YTDDuration | 300000000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | CurrentYTDDuration | 757000000 | JPY |
| Increase decrease on net defined benefit assets decrease increase in retirement benefit asset | Prior1YTDDuration | － | JPY |
| Increase decrease on net defined benefit assets decrease increase in retirement benefit asset | CurrentYTDDuration | -64000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | Prior1YTDDuration | 30000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | CurrentYTDDuration | 251000000 | JPY |
| Interest and dividends income ope cf | Prior1YTDDuration | -996000000 | JPY |
| Interest and dividends income ope cf | CurrentYTDDuration | -1254000000 | JPY |
| Interest expenses ope cf | Prior1YTDDuration | 2096000000 | JPY |
| Interest expenses ope cf | CurrentYTDDuration | 2023000000 | JPY |
| Foreign exchange losses gains ope cf | Prior1YTDDuration | -1839000000 | JPY |
| Foreign exchange losses gains ope cf | CurrentYTDDuration | -5969000000 | JPY |
| Loss gain on sales of investment securities ope cf | Prior1YTDDuration | -107000000 | JPY |
| Loss gain on sales of investment securities ope cf | CurrentYTDDuration | -213000000 | JPY |
| State subsidy ope cf | Prior1YTDDuration | -0 | JPY |
| State subsidy ope cf | CurrentYTDDuration | － | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1YTDDuration | -226000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | CurrentYTDDuration | -2148000000 | JPY |
| Decrease increase in inventories ope cf | Prior1YTDDuration | -6967000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |